InsiderTrades.com logo

ARTV Insider Trading

Insider Ownership Percentage: 21.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $244,162.50

Artiva Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Artiva Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Artiva Biotherapeutics Share Price & Price History

Current Price: $3.78
Price Change: ▲ Price Increase of +0.2 (5.59%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for ARTV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Artiva Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2025Fred AslanCEOSell6,375$3.38$21,547.50343,999View SEC Filing Icon  
10/17/2025Fred AslanCEOSell25,500$6.00$153,000.00356,721View SEC Filing Icon  
8/15/2025Fred AslanCEOSell25,500$2.73$69,615.00386,693View SEC Filing Icon  
7/22/2024Global Strategic Fund I VenbioMajor ShareholderBuy416,666$12.00$4,999,992.001,936,637View SEC Filing Icon  
7/22/2024Yong-Jun HuhDirectorBuy2,083,332$12.00$24,999,984.003,306,900View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Artiva Biotherapeutics (NASDAQ:ARTV)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARTV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Artiva Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025Qube Research & Technologies Ltd25,552$73K0.0%-34.0%0.104%Search for SEC Filing on Google Icon
11/17/2025Prelude Capital Management LLC14,302$41K0.0%N/A0.058%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC262,160$0.75M0.0%-19.8%1.068%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC798,397$2.29M0.0%+419.3%3.252%Search for SEC Filing on Google Icon
11/17/2025Bank of America Corp DE16,145$46K0.0%+225.8%0.066%Search for SEC Filing on Google Icon
11/13/2025Landscape Capital Management L.L.C.39,133$0.11M0.0%N/A0.160%Search for SEC Filing on Google Icon
11/13/2025BNP Paribas Financial Markets118,547$0.34M0.0%+14,463.5%0.485%Search for SEC Filing on Google Icon
8/15/2025Bridgeway Capital Management LLC35,000$53K0.0%N/A0.143%Search for SEC Filing on Google Icon
8/14/2025Jane Street Group LLC44,215$67K0.0%N/A0.181%Search for SEC Filing on Google Icon
8/14/2025Qube Research & Technologies Ltd38,692$58K0.0%N/A0.158%Search for SEC Filing on Google Icon
8/13/2025Marshall Wace LLP52,213$79K0.0%N/A0.214%Search for SEC Filing on Google Icon
8/8/2025Geode Capital Management LLC159,041$0.24M0.0%-61.3%0.653%Search for SEC Filing on Google Icon
8/1/2025Y Intercept Hong Kong Ltd31,567$48K0.0%N/A0.130%Search for SEC Filing on Google Icon
7/31/2025Ground Swell Capital LLC24,849$38K0.1%N/A0.102%Search for SEC Filing on Google Icon
5/15/2025venBio Partners LLC1,198,975$3.60M2.9%-21.1%4.921%Search for SEC Filing on Google Icon
5/12/2025Nuveen LLC47,892$0.14M0.0%N/A0.197%Search for SEC Filing on Google Icon
5/9/2025Charles Schwab Investment Management Inc.54,881$0.17M0.0%+26.1%0.225%Search for SEC Filing on Google Icon
2/17/2025Deutsche Bank AG21,423$0.22M0.0%N/A0.088%Search for SEC Filing on Google Icon
2/17/2025Bank of America Corp DE10,817$0.11M0.0%-39.3%0.045%Search for SEC Filing on Google Icon
2/17/2025BNP Paribas Financial Markets9,879$100K0.0%+262.1%0.041%Search for SEC Filing on Google Icon
2/14/2025Northern Trust Corp117,112$1.18M0.0%+3.8%0.482%Search for SEC Filing on Google Icon
2/13/2025Barclays PLC24,161$0.24M0.0%+23.2%0.099%Search for SEC Filing on Google Icon
2/13/2025Wells Fargo & Company MN8,616$87K0.0%+64.0%0.035%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC315,758$3.18M0.0%+2.2%1.300%Search for SEC Filing on Google Icon
2/12/2025Norges Bank30,000$0.30M0.0%N/A0.124%Search for SEC Filing on Google Icon
2/12/2025JPMorgan Chase & Co.37,619$0.38M0.0%+250.7%0.155%Search for SEC Filing on Google Icon
2/6/2025Charles Schwab Investment Management Inc.43,526$0.44M0.0%+8.0%0.179%Search for SEC Filing on Google Icon
1/30/2025Rhumbline Advisers12,879$0.13M0.0%-13.1%0.053%Search for SEC Filing on Google Icon
1/24/2025China Universal Asset Management Co. Ltd.5,150$52K0.0%N/A0.021%Search for SEC Filing on Google Icon
12/26/2024JPMorgan Chase & Co.10,726$0.17M0.0%N/A0.044%Search for SEC Filing on Google Icon
11/27/2024Franklin Resources Inc.520,301$7.44M0.0%N/A2.142%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC19,616$0.30M0.0%N/A0.081%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC308,930$4.77M0.0%N/A1.272%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC19,616$0.30M0.0%N/A0.081%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP194,108$2.91M0.0%N/A0.799%Search for SEC Filing on Google Icon
11/15/2024State Street Corp86,559$1.34M0.0%N/A0.356%Search for SEC Filing on Google Icon
11/15/2024Samsara BioCapital LLC291,666$4.51M0.9%N/A1.201%Search for SEC Filing on Google Icon
11/15/2024RA Capital Management L.P.9,853,302$152.23M1.8%N/A40.565%Search for SEC Filing on Google Icon
11/15/2024RTW Investments LP148,844$2.30M0.0%N/A0.613%Search for SEC Filing on Google Icon
11/14/2024Acuta Capital Partners LLC44,000$0.68M0.6%N/A0.181%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC8,733$0.14M0.0%N/A0.036%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets2,728$42K0.0%N/A0.011%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.40,293$0.62M0.0%N/A0.166%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Artiva Biotherapeutics logo
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Read More on Artiva Biotherapeutics

Today's Range

Now: $3.78
Low: $3.51
High: $3.79

50 Day Range

MA: $3.61
Low: $2.74
High: $6.01

52 Week Range

Now: $3.78
Low: $1.47
High: $13.14

Volume

61,951 shs

Average Volume

157,244 shs

Market Capitalization

$92.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.1

Who are the company insiders with the largest holdings of Artiva Biotherapeutics?

Artiva Biotherapeutics' top insider investors include:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
  3. Fred Aslan (CEO)
Learn More about top insider investors at Artiva Biotherapeutics.

Who are the major institutional investors of Artiva Biotherapeutics?

Artiva Biotherapeutics' top institutional investors include:
  1. Citadel Advisors LLC — 3.25%
  2. Millennium Management LLC — 1.07%
  3. BNP Paribas Financial Markets — 0.49%
  4. Landscape Capital Management L.L.C. — 0.16%
  5. Qube Research & Technologies Ltd — 0.10%
  6. Bank of America Corp DE — 0.07%
Learn More about top institutional investors of Artiva Biotherapeutics stock.

Which major investors are selling Artiva Biotherapeutics stock?

In the previous quarter, ARTV stock was sold by these institutional investors:
  1. Millennium Management LLC
  2. Qube Research & Technologies Ltd

Which major investors are buying Artiva Biotherapeutics stock?

Within the last quarter, ARTV stock was acquired by institutional investors including:
  1. Citadel Advisors LLC
  2. BNP Paribas Financial Markets
  3. Landscape Capital Management L.L.C.
  4. Prelude Capital Management LLC
  5. Bank of America Corp DE
In the previous year, these company insiders have bought Artiva Biotherapeutics stock:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
Learn More investors buying Artiva Biotherapeutics stock.